Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) has a beta value of 0.73 and has seen 18.42 million shares traded in the recent trading session. The company, currently valued at $21.19B, closed the recent trade at $18.68 per share which meant it lost -$2.85 on the day or -13.24% during that session. The TEVA stock price is -22.06% off its 52-week high price of $22.80 and 38.54% above the 52-week low of $11.48. If we look at the company’s 10-day average daily trading volume, we find that it stood at 9.9 million shares traded. The 3-month trading volume is 9.78 million shares.

The consensus among analysts is that Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is Buy stock at the moment, with a recommendation rating of 1.67. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.59.

Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information

Sporting -13.24% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TEVA stock price touched $18.68 or saw a rise of 16.61%. Year-to-date, Teva- Pharmaceutical Industries Ltd. ADR shares have moved -15.25%, while the 5-day performance has seen it change -15.13%. Over the past 30 days, the shares of Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) have changed -17.42%. Short interest in the company has seen 15.8 million shares shorted with days to cover at 1.26.

Wall Street analysts have a consensus price target for the stock at $25.5, which means that the shares’ value could jump 26.75% from the levels at last check today. The projected low price target is $22.0 while the price target rests at a high of $28.0. In that case, then, we find that the latest price level in today’s session is -49.89% off the targeted high while a plunge would see the stock gain -17.77% from the levels at last check today.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) estimates and forecasts

Figures show that Teva- Pharmaceutical Industries Ltd. ADR shares have underperformed across the wider relevant industry. The company’s shares have gained 12.06% over the past 6 months, with this year growth rate of -3.13%, compared to 26.20% for the industry. Revenue growth from the last financial year stood is estimated to be 3.28%.

2 analysts offering their estimates for the company have set an average revenue estimate of 3.9B for the current quarter. 2 have an estimated revenue figure of 4.17B for the next ending quarter. Year-ago sales stood 3.82B and 4.16B respectively for this quarter and the next, and analysts expect sales will grow by 2.13% for the current quarter and 3.28% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 26.63% over the past 5 years. Earnings growth for 2025 is a modest 11.55% while over the next 5 years, the company’s earnings are expected to increase by 7.98%.

TEVA Dividends

Teva- Pharmaceutical Industries Ltd. ADR is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders

Insiders own 0.00% of the company shares, while shares held by institutions stand at 58.23% with a share float percentage of 58.23%. Investors are also buoyed by the number of investors in a company, with Teva- Pharmaceutical Industries Ltd. ADR having a total of 744.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 42.99 million shares worth more than $698.55 million. As of 2024-06-30, BLACKROCK INC. held 3.8279% of shares outstanding.

The other major institutional holder is FMR LLC, with the holding of over 41.98 million shares as of 2024-06-30. The firm’s total holdings are worth over $682.15 million and represent 3.7381% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Fidelity Contrafund Inc and iShares Core MSCI EAFE ETF. As of Nov 30, 2024, the former fund manager holds about 1.25% shares in the company for having 14.11 shares of worth $261.87 million while later fund manager owns 7.16 shares of worth $132.85 million as of Nov 30, 2024, which makes it owner of about 0.63% of company’s outstanding stock.